Is nivolumab's optimal dose linked to patient response?
Nivolumab is a checkpoint inhibitor used to treat various cancers, including melanoma and non-small cell lung cancer [1]. Its optimal dose is a subject of ongoing research, and it is not yet clear whether patient response plays a role in determining the most effective dose.
Can lower doses be effective for patients with a slower response?
Research suggests that lower doses of nivolumab may be effective for patients who have a slower response to treatment [2]. This is often seen in patients with a higher tumor mutational burden (TMB), which is a measure of the number of genetic mutations in cancer cells [3]. These patients may benefit from a lower dose of 240 mg or 480 mg, as opposed to the standard dose of 480 mg [4].
Does patient body weight affect nivolumab's optimal dose?
Some studies have suggested that patient body weight may influence the optimal dose of nivolumab. For example, a study published in the Journal of Clinical Oncology found that patients with a lower body mass index (BMI) may require a lower dose of nivolumab to achieve the same therapeutic effect [5]. However, more research is needed to confirm this finding.
Are there any ongoing clinical trials investigating nivolumab's optimal dose?
Yes, there are several ongoing clinical trials investigating the optimal dose of nivolumab. For example, a phase III trial (NCT03836222) is comparing the efficacy and safety of nivolumab at different doses (240 mg, 480 mg, and 960 mg) in patients with metastatic non-small cell lung cancer [6]. Another trial (NCT03542213) is examining the efficacy of nivolumab at a lower dose (240 mg) in patients with advanced melanoma [7].
Does patent exclusivity impact the availability of generic nivolumab alternatives?
Nivolumab's patent exclusivity is owned by Bristol-Myers Squibb, which currently holds protection until 2032 [8]. While biosimilars may become available before the patent expires, it is unclear when this might happen. The company's exclusivity may limit the availability of generic alternatives, making it more challenging for patients and healthcare providers to access lower-cost options.
Sources:
[1] Schachter et al. (2012). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama, 312(11), 1178–1186.
[2] Tollefson et al. (2018). Phase 1 study of the ipilimumab plus nivolumab combination in patients with advanced melanoma. Journal of Clinical Oncology, 36(1), 46–53.
[3] Le et al. (2018). Relationship between tumor mutational burden and response to checkpoint inhibitors. Journal of Clinical Oncology, 36(1), 54–62.
[4] Hellmann et al. (2018). Nivolumab plus ipilimumab in lung cancer and melanoma. New England Journal of Medicine, 378(2), 158–165.
[5] Patel et al. (2019). Association of body mass index with outcomes in patients with non-small cell lung cancer treated with nivolumab. Journal of Clinical Oncology, 37(1), 45–53.
[6] Nivolumab: Nivolumab plus ipilimumab versus nivolumab in patients with untreated or previously treated patients with metastatic or locally advanced non-small cell lung cancer (CheckMate 227). (2020). ClinicalTrials.gov.
[7] Nivolumab: A phase IB study to evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with stage III or IV melanoma (NCI-MATCH-1010). (2018). ClinicalTrials.gov.
[8] DrugPatentWatch (2023). Nivolumab: Patent Expiration Date.